England C diff dip "inaccurate" MRSA plateau "no cause for alarm":
This article was originally published in Clinica
Provisional UK data on methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile healthcare-associated bloodstream infections in the last quarter of 2007 show a 0.6% increase and 8% fall, respectively, on the previous quarter. The HPA has dismissed the "plateau" in reducing the incidence of MRSA in England - 1,087 compared with 1,080 during July-September - as falling within reasonable limits and "no cause for alarm". Of the C diff figures - 9,872 (from 10,751) cases aged over 64 years and 2,211 (from 2,507) in the 2-64 age range - the agency acknowledged that they are probably inaccurate, as the data were collected during the transition of refinements to the reporting system. The next quarterly figures, due to be published in July, should prove more meaningful; the HPA is also scheduled to publish final annual statistics for 2007.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.